Clinical response to auranofin in patients with psoriatic arthritis

C. Salvarani, F. Zizzi, P. Macchioni, W. Mantovani, F. Rossi, R. Baricchi, A. Bellelli, N. Capozzoli, L. Frizziero, I. Portioli

Research output: Contribution to journalArticlepeer-review


Fifty-two patients with psoriatic arthritis (PA), treated with auranofin (AF), were entered into a one year prospective, open study. The total group showed a significant increase in frequency of HLA antigens A1 and B38, and a reduction of B5 when compared to healthy controls. There was a remission or an important improvement of disease in the 51 % of 45 patients who completed the study. The rate of withdrawal due to side effects was low (8.8%) and the toxicity was mild in nature (diarrhoea and mucocutaneous rash). We prospectively sought predictors of response using HLA antigens, and clinical and laboratory parameters at the beginning of therapy. The only 3 factors found to be related to outcome were duration of psoriasis, physician and patient assessment of disease activity. No laboratory data or HLA specificities could be associated with substantial response to AF therapy.

Original languageEnglish
Pages (from-to)54-57
Number of pages4
JournalClinical Rheumatology
Issue number1
Publication statusPublished - Mar 1989


  • Auranofin
  • Efficacy
  • HLA antigens
  • Open Study
  • Predictors of Response
  • Psoriatic Arthritis
  • Safety

ASJC Scopus subject areas

  • Rheumatology
  • Immunology


Dive into the research topics of 'Clinical response to auranofin in patients with psoriatic arthritis'. Together they form a unique fingerprint.

Cite this